Why Google Could Transform How We See

Novartis and Google decide to work together on sci-fi eyes.

Jul 20, 2014 at 8:30AM

Google (NASDAQ:GOOGL)(NASDAQ:GOOG) has started making a significant push into wearables, with medical/health care-related applications among the prime targets. Some readers may already have heard of the company's efforts to develop a glucose-sensing smart contact lens that could continuously monitor glucose levels and interface with mobile devices, allowing diabetics more freedom and convenience.

Count eye care giant Novartis (NYSE:NVS) among those who have noticed. Novartis and Google announced on Tuesday that they would work together on smart contact lenses targeting both glucose monitoring and presbyopia. It's hard to say how close to reality (or clinical trials) a functional device might be, but this partnership just may change the landscape of the glucose monitoring market presently dominated by companies like Johnson & Johnson (NYSE:JNJ), Abbott Labs, Roche and Medtronic.

A match that makes sense

On Tuesday, Novartis and Google announced an agreement that will see Novartis license smart lens technology from Google's Google[x] team for the development of medical smart lenses. From the announcement, it seems that this is intended to be a close collaboration with both companies working on product development and Novartis then taking over clinical development and marketing/commercialization.

That Google and Novartis would come together to develop smart contact lenses is not a tremendous surprise. Alcon, the eye care business of Novartis, is one of the world's largest players in both contact lenses and more sophisticated intraocular lenses. What's more, Novartis has made its own attempts in the past at developing smart lenses but hopes that Google's know-how in miniaturization can lead to a commercial product.

It may sound startling that Novartis has worked on a smart/diagnostic contact lens before, but I think many readers would be surprised to learn just how often companies like Novartis try to develop breakthrough technologies like this. Many med-tech companies encourage or at least passively tolerate "mini-skunkworks" within their R&D efforts where engineers and scientists work on more speculative projects.

Diabetes represents a large opportunity

Glucose monitoring is a huge market – worth over $8 billion by Roche's estimation – and one where better technology is still needed. Continuous glucose monitoring can play a crucial role in driving better clinical outcomes, but the market is only about a $350 million today (largely Medtronic and DexCom (DXCM)) and I estimate that at best only about 10% of U.S. Type 1 diabetics currently use continuous monitoring.

Make continuous monitoring easier and painless (put in a lens once a day or perhaps these lenses can stay in for extended periods of time), and the market growth potential is very large. That said, cost is very much a factor. Johnson & Johnson, Abbott, and Roche have all seen their glucose monitoring businesses get pummeled on reimbursement pressures and a smart contact lens is likely to be a pretty exclusive product at first.

Novartis' CEO believes that a prototype could be available early in 2015 and on the market in five years. That's likely a bit ambitious given that the FDA is exceptionally rigorous with the trial demands for new monitoring products, and especially those that feature new technology.

Time for electric eyes?
While the glucose monitoring application of this partnership is likely to get the most media attention, the companies also intend to work on products for presbyopia. These seems like the more "gee whiz" application, with Novartis' CEO Joe Jimenez talking about a lens that could autofocus and automatically adjust as a person looks at close or distant objects.

Maybe I'm indulging a bit too much in my love of scifi here, but if this can work (and management acknowledges it is the less-developed technology today), is it too much to think (hope?) that these lenses could actually enhance vision or offer features like thermal imaging or image recording?

The bottom line
For the here and now, this is just another interesting R&D project within Alcon/Novartis. Even so, it wouldn't surprise me if Johnson & Johnson, which has substantial operations in both glucose monitoring and eye care, took note and perhaps companies like Johnson & Johnson, Roche, and Abbott (which also has some involvement in eye care, including intraocular lenses, but not contacts) get more involved as well. With hundreds of millions of dollars in revenue potential for the right product, it is definitely something to watch over the coming years.

Leaked: A huge under-the-radar opportunity that could leave Google in the dust
Let's face it: the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool recommends Google (A shares) and Johnson & Johnson. The Motley Fool owns shares of Google (A shares) and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers